Fresenius Reaches $250 million GranuFlo Settlement

Source:

On February 22, 2016, it was announced that Fresenius Medical Care reached an agreement to set aside $250 million to settle claims stemming from their GranuFlo and Naturalyte dialysis concentrates.

These products were recalled in 2012 by the FDA after they were identified as contributing to over 900 heart attacks in one year. Unlike other dialysis concentrates, these products contain a chemical which the liver metabolizes into bicarbonate, in addition to the bicarbonate which other products contain. This would essentially give the patient a double-dose of bicarbonate, leading to an overdose which caused complications including low blood pressure and cardiac arrest.

As long as 97% of plaintiffs agree to the terms of the $250 million settlement by July, 2016, the settlement funding will be provided in August, 2016.

If you or a loved one have been injured as a result of Fresenius’ GranuFlo or Naturalyte products, please contact us at (337) 234-7573 for a free evaluation, or visit the GranuFlo Lawyer website for more information.